To assess the efficacy and safety of cinobufacini combined with transcatheter arterial chemoembolization (TACE) on patients with primary liver cancer by Meta-analysis. Methods: Databases, such as PubMed, The Cochrane Library, EMbase, VIP, WanFang Data, CBM and CNKI from to October, 2015 were searched for clinical trials on cinobufacini combined with transcatheter arterial chemoembolization for primary liver cancer. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality. Meta-analysis was performed by RevMan 5.2. Results: Nineteen trials were included with a total of 1 481 patients. The results of meta-analysis showed that the treatment group was superior to the TACE group in terms of short-term efficacy and long-term efficacy, improving the quality of life and causing less adverse reaction partly. Conclusion: Cinobufacini combined with TACE are comparatively more efficient and safer for primary liver cancer.